The estimated Net Worth of Byron L Dorgan is at least $2.09 Milione dollars as of 15 November 2023. Mr. Dorgan owns over 20,000 units of Codexis stock worth over $528,149 and over the last 14 years he sold CDXS stock worth over $1,381,062. In addition, he makes $184,989 as Independent Director at Codexis.
Byron has made over 8 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of CDXS stock worth $42,200 on 15 November 2023.
The largest trade he's ever made was exercising 50,000 units of Codexis stock on 20 January 2021 worth over $531,500. On average, Byron trades about 9,204 units every 85 days since 2011. As of 15 November 2023 he still owns at least 193,461 units of Codexis stock.
You can see the complete history of Mr. Dorgan stock trades at the bottom of the page.
Byron L. Dorgan serves as an Independent Director of Codexis, Inc. Mr. Dorgan brings to our board of directors experience in economic issues, policy making, health care and government affairs. Mr. Dorgan represented the State of North Dakota in the United States Senate from 1992 to January 2011, when he retired. Prior to serving in the United States Senate, Mr. Dorgan served in the United States House of Representatives from 1981 to 1992. During his time in the United States Senate, Mr. Dorgan served in the United States Senate Leadership, first as Assistant Democratic Floor Leader and then as Chairman of the Democratic Policy Committee. He also served as the Chairman of the Committee on Indian Affairs and was the senior Senator on the Appropriations, Energy and Commerce Committees. Prior to being elected to the United States House of Representatives, Mr. Dorgan served as North Dakota State Tax Commissioner from 1969 until 1980. Mr. Dorgan is a New York Times bestselling author of five books, including Take this Job and Ship It: How Corporate Greed and Brain-Dead Politics Are Selling Out America, Reckless! How Debt, Deregulation and Dark Money Nearly Bankrupted America, Blowout; Gridlock and The Girl in the Photograph. Mr. Dorgan is a Senior Fellow at the Bipartisan Policy Center, a Washington DC think tank. Mr. Dorgan is chair of a Non-Profit Board, The Center for Native American Youth (CNAY), working with Native American youth living on Indian Reservations in the U.S. Mr. Dorgan holds a B.S. from the University of North Dakota and an M.B.A. from the University of Denver.
As the Independent Director of Codexis, the total compensation of Byron Dorgan at Codexis is $184,989. There are 5 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.
Byron Dorgan is 77, he's been the Independent Director of Codexis since 2011. There are 2 older and 10 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.
Byron's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 14 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... e John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Codexis executives and other stock owners filed with the SEC include: